ABUS vs CI · P/E 5.4, rev $6.2M vs P/E 2.4, rev $274.90B
Arbutus Biopharma Corp (ABUS) versus Cigna Corp (CI) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Cigna Corp (CI) is a healthcare plans company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CI revenue for 2025-12-31 was $274.90B. Net income was $5.96B. Revenue was up 11.2% from 2024-12-31 to 2025-12-31. CI currently screens at market cap $71.62B and trailing P/E 2.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CI currently screens at market cap $71.62B and trailing P/E 2.4.
Not investment advice. Open the ABUS and CI stock pages for the full models.
Not investment advice.